Table 2.
Patients' clinical characteristics, treatment, and their vitamin D status.
| Number | G | Age | OA | GU | OI | CI | PP | VI | GI | ENT | DA | 25(OH)D | ESR | CRP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 33 | + | + | − | + | − | − | − | + | − | 76 | 6 | <5 |
| 2 | M | 51 | + | + | + | + | + | − | + | + | − | 71 | 7 | 7 |
| 3 | F | 35 | + | + | − | + | − | − | − | + | A | 42 | 25 | 5 |
| 4 | F | 23 | + | + | − | + | − | − | − | + | − | 45 | 11 | <5 |
| 5 | F | 17 | + | + | + | + | − | − | − | − | − | 50 | 6 | <5 |
| 6 | M | 48 | + | + | + | + | − | + | − | − | − | 65 | 12 | <5 |
| 7 | M | 56 | + | − | + | + | − | − | − | + | − | 58 | 2 | <5 |
| 8 | F | 37 | + | + | − | + | − | − | − | − | − | 67 | 12 | <5 |
| 9 | F | 38 | + | + | − | − | + | − | − | − | − | 41 | 8 | <5 |
| 10 | M | 34 | + | + | − | + | − | − | − | − | − | 76 | 17 | <5 |
| 11 | F | 37 | + | + | − | + | − | − | − | − | − | 33 | 5 | <5 |
| 12 | F | 52 | + | + | − | + | − | + | − | − | A | 28 | 28 | <5 |
| 13 | F | 81 | + | + | + | + | − | − | − | − | − | 41 | 14 | <5 |
| 14 | F | 66 | + | + | − | + | − | − | + | − | − | 35 | 33 | <5 |
| 15 | M | 45 | + | + | − | − | − | + | − | − | − | 29 | 7 | <5 |
| 16 | F | 37 | + | + | − | + | − | − | − | − | A | 21 | 28 | 25 |
| 17 | F | 23 | + | + | + | + | − | − | − | − | − | 53 | 5 | <5 |
| 18 | F | 21 | + | + | − | + | − | − | − | − | − | 26 | 13 | <5 |
| 19 | F | 24 | + | + | − | + | − | − | − | − | A | 49 | 14 | <5 |
G: gender; OA: oral aphthosis; GU: genital ulcers; OI: ocular involvement; CI: cutaneous involvement; PP: pathergy phenomenon; VI: vascular involvement; GI: gastrointestinal involvement; ENT: otolaryngeal involvement; DA: disease activity; A: active disease; 25(OH)D: 25-hydroxyvitamin D (nmol/L); ESR: erythrocyte sedimentation rate (mm/hour); CRP: C-reactive protein (mg/L).